Department of Pharmaceutics and Analytical Chemistry, The Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark.
Br J Pharmacol. 2010 Dec;161(8):1793-805. doi: 10.1111/j.1476-5381.2010.01000.x.
Recently, we identified etodolac as a possible ligand for the human intestinal proton-couple peptide transporter (hPEPT1). This raised the possibility that other non-steroidal anti-inflammatory drugs, and especially ibuprofen, could also interact with hPEPT1. Here, we have assessed the interactions of ibuprofen with hPEPT1.
The uptake of [(14)C]Gly-Sar, [(3)H]Ibuprofen and other radio-labelled compounds were investigated in Madin-Darby canine kidney cells (MDCK)/hPEPT1, MDCK/Mock, LLC-PK(1) or Caco-2 cells. The transepithelial transport of ibuprofen and hPEPT1 substrates was investigated in Caco-2 cell monolayers.
Ibuprofen concentration dependently inhibited hPEPT1-mediated uptake of Gly-Sar in MDCK/hPEPT1 cells (K(i)(app) = 0.4 mM) but uptake of ibuprofen in Caco-2 cells and MDCK/hPEPT1 cells was not inhibited by hPEPT1 substrates. The maximum uptake rate for Gly-Sar uptake was reduced from 522 pmol·min(-1)·cm(-2) to 181 pmol·min(-1)·cm(-2) and 78 pmol·min(-1)·cm(-2) in the presence of 0.5 mM and 1 mM ibuprofen, respectively. The interaction between ibuprofen and hPEPT1 was thus non-competitive. In LLC-PK1 cells, ibuprofen (1 mM) did not influence the transporter-mediated uptake of glycine or α-methyl-D-glycopyranoside. In Caco-2 cell monolayers the absorptive transport of δ-aminolevulinic acid was reduced by 23% and 48% by ibuprofen (1 and 10 mM), respectively. Likewise the transport of Gly-Sar was reduced by 23% in the presence of ibuprofen (1 mM).
Ibuprofen is a non-competitive inhibitor of hPEPT1. As ibuprofen reduced the transepithelial transport of δ-aminolevulinic acid, drug-drug interactions between ibuprofen and hPEPT1 drug substrates at their site of absorption are possible if administered together.
最近,我们发现依托度酸可能是人类肠道质子偶联肽转运体(hPEPT1)的配体。这就提出了一种可能性,即其他非甾体抗炎药,特别是布洛芬,也可能与 hPEPT1 相互作用。在这里,我们评估了布洛芬与 hPEPT1 的相互作用。
在 Madin-Darby 犬肾细胞(MDCK)/hPEPT1、MDCK/模拟、LLC-PK(1)或 Caco-2 细胞中研究了[(14)C]Gly-Sar、[(3)H]Ibuprofen 和其他放射性标记化合物的摄取。在 Caco-2 细胞单层中研究了布洛芬和 hPEPT1 底物的跨上皮转运。
布洛芬浓度依赖性地抑制 MDCK/hPEPT1 细胞中 hPEPT1 介导的 Gly-Sar 摄取(K(i)(app) = 0.4 mM),但 hPEPT1 底物不抑制 Caco-2 细胞和 MDCK/hPEPT1 细胞中布洛芬的摄取。Gly-Sar 摄取的最大摄取率分别从 522 pmol·min(-1)·cm(-2)降低至 181 pmol·min(-1)·cm(-2)和 78 pmol·min(-1)·cm(-2),存在 0.5 mM 和 1 mM 布洛芬时。因此,布洛芬与 hPEPT1 的相互作用是非竞争性的。在 LLC-PK1 细胞中,布洛芬(1 mM)不影响甘氨酸或α-甲基-D-吡喃糖苷的转运体介导摄取。在 Caco-2 细胞单层中,δ-氨基乙酰丙酸的吸收转运分别被布洛芬(1 和 10 mM)降低了 23%和 48%。同样,在存在布洛芬(1 mM)的情况下,Gly-Sar 的转运也降低了 23%。
布洛芬是 hPEPT1 的非竞争性抑制剂。由于布洛芬降低了 δ-氨基乙酰丙酸的跨上皮转运,如果同时给予,布洛芬和 hPEPT1 药物底物之间在吸收部位可能发生药物-药物相互作用。